Sets the Institute for OneWorld Health (iOWH), a company dedicated to the production of drugs for neglected diseases and the first nonprofit pharmaceutical company in the world. Founded in 2000 by Dr. Victoria Hale, iOWH took expired and patent compounds donated and developed them through all phases of clinical testing and approval in drugs to the world’s most devastating diseases, usually occurring in third-world countries where perceived profitable markets not fight yet. By 2004, … Read more »

Sets the Institute for OneWorld Health (iOWH), a company dedicated to the production of drugs for neglected diseases and the first nonprofit pharmaceutical company in the world. Founded in 2000 by Dr. Victoria Hale, iOWH took expired and patent compounds donated and developed them through all phases of clinical testing and approval in drugs to the world’s most devastating diseases, usually occurring in third-world countries where perceived profitable markets not fight yet. Until 2004 iOWH presents its first Phase 3 clinical trial of paromomycin, a drug for visceral leishmaniasis was developed that as many as 200,000 people killed every year in India, Bangladesh, Sudan, Brazil and Nepal. His next task was to create partnerships with other organizations and to distribute the drug to form. Focuses on Hale strategy for iOWH future, with particular reference to its core competencies and mission.
«Hide

from
Johanna Mair,
Oliver Schoen
Source: IESE
33 pages.
Release date: 01 April, 2005. Prod #: IES109-PDF-ENG
New Model for the Pharmaceutical Industry: The Institute for OneWorld Health HBR case solution

[related_post themes="flat"]